Ligand Pharmaceuticals Incorporated (LGND) Q3 2007 Earnings Results

Ligand Pharmaceuticals Misses on EPS — Stock Down 0.59%

Ligand Pharmaceuticals reported a loss per share of $-0.05, which was below expectations. The stock reacted negatively, dropping 0.59%. The lack of revenue data and forward guidance adds uncertainty for investors, contributing to the stock's decline.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.05	N/A	-150.00%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management's tone was defensive, indicating awareness of challenges ahead. They refrained from providing any forward guidance.

Management did not provide specific guidance for future quarters.

The company acknowledged challenges but did not elaborate on specific strategies.

Ligand Pharmaceuticals Misses on EPS — Stock Down 0.59%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Misses on EPS — Stock Down 0.59%

Key numbers

Management commentary